These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Neuroendocrine aspects in monitoring of dopaminergic drugs in man. Hietala J; Koulu M; Scheinin M; Syvälahti E Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):451-4. PubMed ID: 3935892 [TBL] [Abstract][Full Text] [Related]
27. Effect of apomorphine hydrochloride administration on serum concentrations of prolactin and growth hormone in cattle. Gorewit RC Experientia; 1981 Feb; 37(2):204-6. PubMed ID: 7238762 [No Abstract] [Full Text] [Related]
28. Effects of dopamine agonists in tardive dyskinesia. Smith RC; Tamminga CA; Haraszti J; Pandey GN; Davis JM Am J Psychiatry; 1977 Jul; 134(7):763-8. PubMed ID: 869053 [TBL] [Abstract][Full Text] [Related]
29. Noradrenergic challenges in the affective disorders. Siever L; Insel T; Uhde T J Clin Psychopharmacol; 1981 Jul; 1(4):193-206. PubMed ID: 7028801 [TBL] [Abstract][Full Text] [Related]
30. Neuropharmacologic control of neuroendocrine function in man. Frohman LA; Stachura ME Metabolism; 1975 Feb; 24(2):211-34. PubMed ID: 234567 [No Abstract] [Full Text] [Related]
31. Neuroendocrine profiles in mood disorders. Linkowski P Int J Neuropsychopharmacol; 2003 Jun; 6(2):191-7. PubMed ID: 12890312 [TBL] [Abstract][Full Text] [Related]
32. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects. Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563 [TBL] [Abstract][Full Text] [Related]
34. Neurochemical mechanisms in the affective disorders and neuroendocrine correlates. Risch SC; Kalin NH; Murphy DL J Clin Psychopharmacol; 1981 Jul; 1(4):180-5. PubMed ID: 6117585 [TBL] [Abstract][Full Text] [Related]
35. Growth hormone and prolactin response to apomorphine in bipolar and unipolar depression. McPherson H; Walsh A; Silverstone T J Affect Disord; 2003 Sep; 76(1-3):121-5. PubMed ID: 12943941 [TBL] [Abstract][Full Text] [Related]
36. Suicidal behavior and growth hormone response to apomorphine test. Pitchot W; Hansenne M; Moreno AG; Ansseau M Biol Psychiatry; 1992 Jun; 31(12):1213-9. PubMed ID: 1391282 [TBL] [Abstract][Full Text] [Related]
37. Differential effects of L-dopa and apomorphine on glucagon secretion in man: evidence against central dopaminergic stimulation of glucagon. Lorenzi M; Tsalikian E; Bohannon NV; Gerich JE; Karam JH; Forsham PH J Clin Endocrinol Metab; 1977 Dec; 45(6):1154-8. PubMed ID: 591612 [TBL] [Abstract][Full Text] [Related]
38. Drug-induced growth hormone and prolactin responses in schizophrenia research. Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495 [TBL] [Abstract][Full Text] [Related]
39. Dopaminergic sensitivity and cocaine abuse: response to apomorphine. Hollander E; Nunes E; DeCaria CM; Quitkin FM; Cooper T; Wager S; Klein DF Psychiatry Res; 1990 Aug; 33(2):161-9. PubMed ID: 2243893 [TBL] [Abstract][Full Text] [Related]
40. Variability of hormonal responses to a series of neuroendocrine challenges in depressed patients. Winokur A; Amsterdam J; Caroff S; Snyder PJ; Brunswick D Am J Psychiatry; 1982 Jan; 139(1):39-44. PubMed ID: 6798884 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]